Prodrug of 5-FU for cancer therapy
The activity of 5-FU is markedly limited by its rapid degradation into 5-FUH 2fluoro-5,6-dihydrouracil) via the action of the cytosolic enzyme DPD (Dihydro pyrimidinedehydrogenase),the first enzyme in the catabolic cycle of 5 -FU. It has been demonstrated that this enzymedeactivates more than 85% of the injected dose of 5-FU. Little drug is thus left for anabolism. Thisencourages the need of prodrug of 5 F-U.
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2025-01-01
- DOI
- https://doi.org/10.5281/zenodo.16927114
- Primary Topic
- Geochemistry and Geologic Mapping
- Type
- article
- Field-Weighted Citation Impact
- 0.00